Health Care [ 4/12 ] | Pharmaceuticals [ 14/72 ]
NASDAQ | Common Stock
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases.
It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers.
Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 14, 24 | -0.17 Increased by +74.63% | -0.21 Increased by +19.05% |
| Mar 14, 24 | -0.59 Decreased by -11.32% | -0.50 Decreased by -18.00% |
| Nov 9, 23 | -0.51 Increased by +15.00% | -0.62 Increased by +17.74% |
| Aug 10, 23 | -0.56 Increased by +21.13% | -0.73 Increased by +23.29% |
| May 15, 23 | -0.67 Increased by +20.24% | -0.58 Decreased by -15.52% |
| Mar 21, 23 | -0.53 Increased by +26.39% | -0.53 |
| Nov 9, 22 | -0.60 Increased by +16.67% | -0.66 Increased by +9.09% |
| Aug 10, 22 | -0.71 Increased by +15.48% | -0.60 Decreased by -18.33% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 1.56 M Increased by +87.82% | -1.69 M Increased by +14.84% | Decreased by -108.39% Increased by +54.66% |
| Jun 30, 23 | 1.13 M Increased by +144.99% | -1.87 M Increased by +16.22% | Decreased by -165.10% Increased by +65.80% |
| Mar 31, 23 | 810.41 K Increased by +93.70% | -2.45 M Decreased by -12.95% | Decreased by -302.85% Increased by +41.69% |
| Dec 31, 22 | 796.37 K Increased by +120.86% | -1.77 M Decreased by -5.88% | Decreased by -222.34% Increased by +52.06% |
| Sep 30, 22 | 832.10 K Decreased by -10.57% | -1.99 M Decreased by -1.00% | Decreased by -239.05% Decreased by -12.94% |
| Jun 30, 22 | 461.80 K Increased by +95.15% | -2.23 M Increased by +2.67% | Decreased by -482.78% Increased by +50.13% |
| Mar 31, 22 | 418.38 K Increased by +362.70% | -2.17 M Increased by +16.60% | Decreased by -519.35% Increased by +81.98% |
| Dec 31, 21 | 360.57 K Increased by +1.47 K% | -1.67 M Increased by +26.26% | Decreased by -463.81% Increased by +95.29% |